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Abstract Protein kinase C (PKC) family members are down- 
regulated by chronic activation at the protein level in most cell 
types. In T84 human epithelial cells 12-O-tetradecanoyl phorbol 
13-acetate (TPA) caused persistent ranslocation of PKC 8 to 
the membrane compartment and a 400% increase of PKC 5- 
mRNA after 24 h. In contrast, PKC a protein was completely 
downregulated and its mRNA was decreased to 60% of control 
levels after 24 h. This is the first report of PKC 5-mRNA 
upregulation by TPA which was previously only shown for 
PKC[~. In view of the antimitogenic actions of PKC 5 this pattern 
of regulation may serve to preserve growth control even in the 
presence of chronic cell activation. 
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1. Introduction 
The protein kinase C (PKC) family of multifunctional ser- 
ine/threonine protein kinases consists of at least 12 family 
members which are widely distributed in eukaryotes [1-3]. 
Among those PKC ~x [2], a 'classical' (cPKC) Ca2+-dependent 
isoform, and PKC 8 [3], a 'novel' (nPKC) Ca2+-independent 
isoform are present in most central nervous and peripheral 
cell types [1,4]. Prolonged activation of  PKC c~ by phorbol 
esters caused a rapid loss of PKC enzyme activity and protein 
while PKC cx-mRNA was not affected in several studies [5,6]. 
Much less is known about the regulation of the more recently 
discovered PKC 8, particularly at the mRNA level. PKC ~5 
was shown to exert antiproliferative actions upon overexpres- 
sion in CHO [7] or N IH  3T3 cells [8,9] and to cause differ- 
entiation in myeloid 32D cells [10]. PKC 8 is also a candidate 
for mediating the antiproliferative ffects of phorbol esters 
observed in some pituitary and colon carcinoma cell lines 
[11,12]. Its mode of regulation may determine long-term re- 
sponses of cells to prolonged activation of PKC in vivo, in 
particular with regard to the regulation of proliferation [13]. 
For  example, we observed alterations of PKC 6 protein and 
mRNA expression in human colonic and pituitary adenomas 
[141. 
To learn more about its mode of regulation we examined 
the responses of PKC 8 protein and mRNA to chronic activa- 
tion by the phorbol ester TPA in a highly differentiated hu- 
man colon carcinoma cell line T84. For  comparison we also 
examined the regulation of PKC ~ which has not previously 
been investigated in this cell type. 
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2. Materials and methods 
Chemicals were purchased from Merck, Darmstadt, Germany and 
restriction enzymes from Boehringer, Mannheim, Germany except 
when noted otherwise and were of the highest purity available. 
2.1. Construction of PKC probes 
Isotype specific human PKC cDNA fragments were subcloned into 
pSP72 or pSP73 plasmids (Serva, Heidelberg, Germany). A 194 bp 
Sau3A fragment of G3PDH derived from a G3PDH cDNA fragment 
(ITC, Heidelberg, Germany) was inserted into a BamHI restricted 
pSP73 plasmid in 3'5' orientation. 
A PKC ct fragment was generated by reverse transcription with 
MMLV reverse transcriptase (Gibco, Eggenstein, Germany) of 1 gg 
RNA of T84 cells and PCR according to Kawasaki [15]. PCR was 
performed with the upper primer ATTTAAGGAACCACAAGCA 
and lower primer AGACCCTGAACAGTTGATC for 40 cycles at 
1 min 93°C, 1 min 49°C and 1 min 30 s 72°C. The 882 bp cDNA 
fragment was restricted with MaelI and StuI and the 363 bp fragment 
was inserted into a pSP73 plasmid restricted with ClaI and PvulI. 
The PKC 8 fragment was obtained from human blood cell buffy 
coat cDNA. A 498 bp cDNA fragment of PKC 8 was detected using 
the upper primer CTGCTCTGGGGACTGGTGAA and lower pri- 
mer GCAGATGAGGTGGGTGAGAAAG by PCR with reverse 
transcription. For this purpose 1 gg RNA were transcribed with 
MMLV reverse transcriptase (Gibco, Eggenstein, Germany) according 
to Kawasaki [15]. Amplification of cDNA was performed for 40 cycles 
at 1 min 15 s 92°C, 1 min 30 s 56°C and 1 rain 72°C. The 498 bp PCR 
product was restricted with MaelI and HindlII and the 315 bp frag- 
ment was inserted into a ClaI and HindlII restricted pSP73 plasmid. 
All inserts were sequenced according to Sanger. 
2.2. Transcription in vitro 
Plasmids containing isotype specific gene probes for the PKC sub- 
types ~, 8 or G3PDH were linearized with BglI, HpaI and XbaI, 
respectively. PKC ct fragments were transcribed with T7 RNA poly- 
merase and PKC ~ and G3PDH with Sp6 RNA polymerase (Boeh- 
ringer Mannheim, Germany). The transcripts had a specific activity of 
2000 Ci/mmol except G3PDH which had a specific activity of 20 Ci/ 
mmol. Complete transcription of the probes was controlled on dena- 
turing polyacrylamide g ls. 
2.3. RNase protection analysis 
In brief, 20 gg of total cellular RNA obtained using an acid phenol- 
chloroform extraction method [16] was hybridized with 300000 cpm 
in 20 gl 40 mM PIPES pH 6.4, 0.4 M NaC1, 1 mM EDTA, 80% 
formamide. After submerse denaturation for 10 min at 85°C and 
cooling down slowly overnight o 54°C RNase digestion was per- 
formed with 1000 U/ml RNase T1 (Boehringer Mannheim, Germany), 
5 mM EDTA, 0.3 M NaCI, 10 mM Tris-HC1 pH 7.4 for 1 h at 30°C. 
RNase digestion was stopped with proteinase K and phenol chloro- 
form extraction. After ethanol precipitation, washing and denaturing 
at 95°C for 3 min probes were run on a 6% denaturing polyacrylamide 
gel at 22 W for 2.5 h. Autoradiography was performed for 1-2 days 
using MP-hyperfilms (Amersham, Buchler, Germany). For quantifica- 
tion of PKC signals autoradiograms were scanned by laser densitom- 
etry (Molecular Dynamics, Sunnyvale, USA) relative to G3PDH 
using Quantlmage software (Molecular Dynamics, Version 3.2 beta). 
2.4. Cell culture 
T84 cells were grown in DMEM/F12 (1:1) medium with penicillin 
and streptomycin (Boehringer Mannheim, Germany) containing 5% 
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FCS at 37°C in a humid atmosphere containing 5% CO2. Cells were 
subcultured with HBSS, 1 mM EDTA, 0.025% trypsin, pH 7.2 before 
reaching confluency and were grown on 10 cm ~3 petri dishes or 96 
well plates for 2 days prior to experiments. 
2.5. Immunoblotting 
Denaturing el electrophoresis was performed with 8% polyacryla- 
mide gels according to Laemmli [17]. Proteins were blotted by alkaline 
semidry transfer [18,19] to polyvinylidene fluoride (PVDF) mem- 
branes (Millipore, Bedford, USA). Prestained molecular weight mar- 
kers (Sigma, St. Louis, USA) were run in parallel to protein probes to 
control for completeness of transfer. Polyclonal antibodies were used 
generated against oligopeptides of rat PKC ct (amino acids 313 326; 
Boehringer Mannheim, Germany) and human PKC 8 (amino acids 
658-676; Calbiochem, La Jolla, USA; cat. no. 539607, lot. no. 
B10897). Membranes were blocked in TBS (50 mM Tris-HCl pH 
7.5, 150 mM NaC1, 0.05% Tween 20 (Sigma, Deisenhofen, Germany) 
with 2% non-fat dry milk for 1 h at room temperature. Antibodies to 
PKC ct were incubated at 4 lag/ml and PKC 8 at 10 gl/ml in TBS with 
1% non-fat dry milk for 2 h at room temperature. Visualization of 
PKC signals was achieved with protein A conjugated to alkaline 
phosphatase (Calbiochem, La Jolla, USA) and BCIP/NBT (Sigma, 
Deisenhofen, Germany). For evaluation of the specificity of PKC 
signals we used single recombinant human PKC isotype proteins (Cal- 
biochem, La Jolla, USA) generated in insect cells and competition 
with the peptides against which the antibodies were generated accord- 
ing to the manufacturers' protocols. 
2.6. Quantification of immunoblots 
PVDF membranes of PKC immunoblots were made transparent by 
soaking in 60% dimethyl sulfoxide and 40% absolute thanol accord- 
ing to [20]. Membranes were sealed in plastic wraps and scanned with 
a laser densitometer (Molecular Dynamics). Relative intensities of 
PKC expression were determined by integrating the PKC signal sub- 
tracted from background signal using Quantlmage software (Molecu- 
lar Dynamics) which gave a linear signal between 5 and 40 gg protein 
loaded per lane with the amounts of PKC present in T84 cells. 
2. 7. Cytosolic and membrane homogenates and quantification of pro- 
teins 
Cells grown to 80% confluency on 10 cm ~3 cell culture plates were 
washed in PBS and homogenized in cold 0.25 M sucrose, 10 mM 
EGTA, 2 mM EDTA, 20 mM Tris-HC1 pH 7.5, 0.1% mercaptoetha- 
nol, 1 mM phenylmethylsulfonyl fluoride (added freshly), 0.1% (w/v) 
leupeptin, 0.1% aprotinin (Bayer AG, Wuppertal, Germany) by soni- 
fication (Braun, Melsungen, Germany) with 3 pulses of 10 s at 100 W 
on ice. All subsequent steps were performed at 4°C. Homogenates 
were centrifuged at 100000×g for 30 rain. Supernatant was collected 
as the cytosolic fraction; the sediment was resuspended in homogeni- 
zation buffer containing additionally 1%0 (v/v) Nonidet P-40. After 
incubation for 30 min on ice the homogenate was centrifuged at 
14000xg for 30 min at 4°C. Supernatant was collected as the mem- 
brane fraction. Protein was determined by a modification [21] of the 
Bradford assay [22]. The remaining cytoskeletal proteins contained no 
detectable PKC protein. 
3. Results 
PKC 8 protein was detectable by immunoblotting of T84 
cell cytosolic and membrane protein and was completely 
eliminated by preincubation of the antibody with the immu- 
nogen (Fig. 1A). Treatment of T84 cells with TPA resulted in 
the rapid reduction of cytosolic PKC 8 being apparent after 
30 min (Fig. 2A, lanes 5,6) and led to almost complete loss 
after 24 h (Fig. 2A, lanes 1,2). The membrane-associated frac- 
tion increased in parallel within 30 min (Fig. 2A, lanes 5,6) 
and persisted for 24 h (Fig. 2A, lanes 1,2) indicating contin- 
ued translocation of PKC 8 from cytosol to membrane. PKC 
8-mRNA was demonstrated by ribonuclease protection ana- 
lysis (RPA) in 20 gg of unselected RNA.  A G3PDH probe 
labeled to a low specific activity was hybridized together with 
the PKC 8 probe and served as an internal marker for RNA 
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Fig. 1. Detection of PKC 8 (A) and PKC ct (B) expression by im- 
munoblots. Cytosolic or membrane proteins were separated by 
SDS-PAGE using 20 gg per lane for PKC8 and 40 gg per lane for 
PKCet. For PKC 8 and ct lanes 1,3 show isotype specific detection 
in cytosol and membrane fractions, respectively; lanes 2,4 show the 
corresponding competition with the peptide against which the iso- 
type specific antibodies were generated. Positions of molecular 
weight markers in kDa are shown to the right of each analysis. 
loading. Treatment with 100 nM TPA caused an elevation of 
PKC 8-mRNA which was detectable after 4 h (Fig. 3A, lanes 
5,6), persisting throughout he experiment and reaching 400% 
of basal values after 24 h (Fig. 3A, lanes 3,4). 
In order to control for the possible regulation of G3PDH 
by TPA Northern blotting was performed which did not show 
a significant change of its expression. 
PKC ~ was expressed at relatively low but detectable levels 
in the cytosolic compartment of T84 cells while the membrane 
signal was at the limit of detection (Fig. 1B). Cytosolic levels 
decreased upon TPA treatment and were almost undetectable 
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Fig. 2. Time-dependent expression of PKC ~ (A) and ct (B) protein 
during treatment of T84 cells with 100 nM TPA. 40 ~tg of cytosolic 
or membrane protein were analyzed per lane. Lanes 1,2 show sig- 
nals of PKC ~i or ct of cells treated with TPA for 24 h, lanes 3,4 
for 4 h and lanes 5,6 for 30 min. DMSO (24 h for controls) content 
was 0.1% (v/v) in all experiments. One representative blot is shown 
and the graphic analysis shows the results of 3 independent analyses 
relative to DMSO-treated cells as obtained by laser densitometry. 
after 24 h (Fig. 2B, lanes 1,2). The membrane signal of PKC ct 
showed no detectable change between 30 min and 24 h despite 
repeated attempts (Fig. 2B). PKC et-mRNA was readily de- 
tectable by RPA and suprisingly also decreased over 24 h of 
TPA treatment to 60% of initial levels (compare lane 
I=DMSO with lanes 2,3=24 h TPA;  Fig. 3B). The time 
course of the decrease of PKC ct-mRNA was relatively slow 
and a decrease was not yet apparent after 4 h of TPA treat- 
ment (Fig. 3B, lanes 4,5). 
4. Discussion 
Persistent activation of PKC by phorbol esters has been 
shown to lead to downregulation of both classical and novel 
PKCs in numerous cell types (for review see [4]). Regarding 
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Fig. 3, Time course of PKC 5 and a mRNA expression during treatment of T84 cells with 100 nM TPA. One representative RNase protection 
analysis of 20 gg total cellular RNA is shown in the upper panel. Each lane shows results from independent RNA extracts. Two 10 cm O 
plates of T84 cells were treated with 100 nM TPA for 24 h (PKC & lanes 3,4; PKC ~: lanes 2,3), 4 h (PKC 5: lanes 5,6; PKC ~: lanes 4,5), 
30 rain (PKC 5: lanes 7,8; PKC ~: lanes 6,7). 24 h DMSO (0.1% (v/v)) treated cells were analyzed in lanes 1,2 for PKC 5 or in lane 1 for 
PKC ~. PKC 5 or g and G3PDH indicate the position of the protected fragments. The probes of transcription i  vitro were used as molecular 
weight markers (PKC ~ = 396 nt, PKC 5 = 397 nt, G3PDH = 245 nt). The analyses of three independent experiments are shown in the lower pa- 
nel as obtained by laser densitometry in which RNA signals were corrected for G3PDH. 
PKC ot phorbol esters have been shown to accelerate degra- 
dation of the enzyme without affecting mRNA levels in N IH  
3T3 or B82L cells [5,6]. In primary melanocytes a TPA-in- 
duced decrease of PKC ct-mRNA similar to that described 
in this study has been reported [23]. This demonstrates that 
transcriptional or posttranscriptional downregulation of PKC 
may occur in addition to posttranslational regulation. 
In contrast, PKC ~ was activated by TPA treatment as 
indicated by translocation and was persistently elevated in 
the membrane compartment. In parallel there was a persistent 
400% increase of PKC &mRNA induced by TPA. This is 
reminiscent of the behaviour of PKC 13 which was shown to 
be upregulated by activation of PKC in lymphocytes [24], 
melanocytes [23], pituitary cells [25] and PC12 cells [26] at 
the protein and mRNA level. This upregulation is explained 
by the finding that the PKC 13-promoter is positively regulated 
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by TPA [27,28]. The human PKC ~-promoter has not been 
reported to date but may be expected to contain similiar se- 
quences. Alternatively, posttranscriptional regulation may oc- 
cur. 
The levels of PKC 8-protein were not elevated to the same 
degree as those of mRNA. However, it is important o stress 
that PKC 8 was persistently elevated in the membrane com- 
partment by TPA which caused downregulation of PKC ct to 
undetectable vels. Although this was not investigated in the 
present study, levels of PKC protein are thought to be con- 
trolled by the rate of degradation upon translocation to the 
membrane by calpain or similar proteases. In the case of PKC 
t~ this process appears to be rapid and the loss of PKC protein 
is accentuated by a decrease in its mRNA levels. In the case of 
PKC 8 the degradation of the protein appears to be counter- 
acted by an elevated rate of resynthesis as suggested by the 
elevated levels of its mRNA. 
PKC 8 has been shown to exert antiproliferative effects in 
several cell types [7-9]. Its upregulation by chronic stimulation 
may thus present a protective mechanism against proliferative 
effects caused by cellular overactivation. Indeed, in T84 cells 
continous treatment with phorbol esters causes a persistent 
decrease of proliferation lasting for at least 18 days (Assert 
and Pfeiffer, unpublished). It will be of interest o study its 
regulation in other cell types. 
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